Shares of Karyopharm Therapeutics, a clinical-stage pharmaceutical company, catapulted 26% amid heavy volume Tuesday after the company said it will provide an overview of topline results from its phase 2b Storm study and the planned development path for selinexor in multiple myeloma (MM) on Sept. 6.
The company confirmed it intends to expand the Storm study evaluating the activity of selinexor in multiple myeloma to include about 120 additional patients with penta-refractory MM.
The volume of intraday trading surged to 1.5 million shares, compared with the stock’s three-month daily average of about 134,000.
